Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SP600125 |
Synonyms | |
Therapy Description |
SP600125 is an ATP-competitive inhibitor of JNK, with activity against JNK1, JNK2, and JNK3 and also TTK (Mps1), which may lead to cell-cycle inhibition and decreased growth of tumor cells (PMID: 19478553, PMID: 11717429, PMID: 16113653, PMID: 32835935). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SP600125 | JNK Inhibitor 5 MPS1 Inhibitor 27 | SP600125 is an ATP-competitive inhibitor of JNK, with activity against JNK1, JNK2, and JNK3 and also TTK (Mps1), which may lead to cell-cycle inhibition and decreased growth of tumor cells (PMID: 19478553, PMID: 11717429, PMID: 16113653, PMID: 32835935). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 loss | colon carcinoma | sensitive | SP600125 | Preclinical | Actionable | In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244). | 22438244 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|